NDA (New Drug Application)
ANDA (Generic Application)
Track protection status across key markets to assess launch feasibility.
It is formulated by 22 pharmaceutical companies such as MERCK SHARP DOHME, SINOTHERAPEUTICS INC, HIKMA and others. It is marketed under 3 brand names, including NOXAFIL, POSACONAZOLE, NOXAFIL POWDERMIX KIT. Available in 4 different strengths, such as 100MG, 300MG/16.7ML (18MG/ML), 40MG/ML and others, and administered through 4 routes including TABLET, DELAYED RELEASE;ORAL, SOLUTION;INTRAVENOUS, SUSPENSION;ORAL and others.
API availability: Loading API feasibility...
Licensing: 22 potential partnersUS Launch window: Loading launch window...
Stay ahead with worldwide patent expiry and latest updates.
FDA approval history for this ingredient
Stay ahead with worldwide patent expiry insights, exclusivity data, and latest updates.
Key expiration dates for US patents covering this ingredient
Stay ahead with worldwide patent expiry insights, market data, and research updates.
Latest drug strengths approved by FDA
| Strength | Route of Administration | Companies | Latest Approval Date |
|---|
Patents approved by the FDA for the ingredient
|
|
Patent Number | Publication Date | Legal Status | Patent Expiry Date | |
|---|---|---|---|---|---|
| {"application_id":"2450","ingredient":"POSACONAZOLE","trade_name":"NOXAFIL","family_id":"3ecf95748df94158a713","publication_number":"US10117951B2","cleaned_patent_number":"10117951","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2029-03-13","publication_date":"2018-11-06","legal_status":"Granted"} | US10117951B2 Formulation | 06 Nov, 2018 | Granted | 13 Mar, 2029 | |
| {"application_id":"2455","ingredient":"POSACONAZOLE","trade_name":"NOXAFIL","family_id":"3ecf95748df94158a713","publication_number":"US8410077B2","cleaned_patent_number":"8410077","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2029-03-13","publication_date":"2013-04-02","legal_status":"Granted"} | US8410077B2 Formulation | 02 Apr, 2013 | Granted | 13 Mar, 2029 | |
| {"application_id":"40752","ingredient":"POSACONAZOLE","trade_name":"NOXAFIL","family_id":"3ecf95748df94158a713","publication_number":"US9750822B2","cleaned_patent_number":"9750822","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2029-03-13","publication_date":"2017-09-05","legal_status":"Granted"} | US9750822B2 Formulation | 05 Sep, 2017 | Granted | 13 Mar, 2029 | |
| {"application_id":"2457","ingredient":"POSACONAZOLE","trade_name":"NOXAFIL","family_id":"7ff6a14f95574c938cff","publication_number":"US9358297B2","cleaned_patent_number":"9358297","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2031-06-24","publication_date":"2016-06-07","legal_status":"Granted"} | US9358297B2 Formulation | 07 Jun, 2016 | Granted | 24 Jun, 2031 | |
| {"application_id":"2456","ingredient":"POSACONAZOLE","trade_name":"NOXAFIL","family_id":"7ff6a14f95574c938cff","publication_number":"US9023790B2","cleaned_patent_number":"9023790","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2031-07-04","publication_date":"2015-05-05","legal_status":"Patented case"} | US9023790B2 Formulation | 05 May, 2015 | Patented case | 04 Jul, 2031 | |
| {"application_id":"34843","ingredient":"POSACONAZOLE","trade_name":"NOXAFIL","family_id":"63f22001fd064021a5c0","publication_number":"US9493582B2","cleaned_patent_number":"9493582","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2033-02-27","publication_date":"2016-11-15","legal_status":"Granted"} | US9493582B2 Formulation | 15 Nov, 2016 | Granted | 27 Feb, 2033 |
Latest clinical trials and research studies for this ingredient
| NCT ID | Title | Status | Phase | Conditions | Start Date | Completion Date |
|---|
Manufacturing Locations
Unlock access to all suppliers of Posaconazole
Note: Patent expirations and exclusivity timelines are dynamic and may shift based on litigation, regulatory extensions, and maintenance filings. Regular monitoring is advised.